Skip to main content

Table 4 Adjuvant chemotherapy regimens and relapses in 48 patients with metaplastic breast cancer

From: Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators

Chemotherapy regimen Number Patient outcome
Cyclophosphamide, methotrexate and fluorouracil 7 Seven relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide 7 Two relapse-free at 45 and 57 months. One alive and well at 62 months after a local recurrence. Two progressed while receiving adjuvant therapy. Two relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide to taxane, paclitaxel/cisplatin/carboplatin 9 Five relapse-free at 30, 53, 66, 69 and 101 months respectively. Four relapsed.
Taxane/paclitaxel, anthracyclines and cyclophosphamide 18 Eight relapse-free at 55, 64, 75, 91, 108, 110, 123 and 156 months respectively. Ten relapsed.
Taxane, anthracyclines and cyclophosphamidein combination with cisplatin/capecitabine 4 Three alive and well at 17, 25 and 39 months after a local recurrence. One alive at 45 months before a local recurrence, alive at 20 months after distant metastasis.
Paclitaxel, anthracyclines and cyclophosphamidein combination with capecitabine/vinorelbine 3 Three alive at 24, 29 and 41 months before a local recurrence, alive at 15, 18 and 25 months after distant metastasis.